Antihemophilic Factor Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 250, 500, 1000, 1500, 2000 IU

Reference Brands: Advate (USA), Afstyla (USA), Helixate FS (USA)

Category: Blood Disorder

Antihemophilic Factor (Factor VIII) is a blood-clotting protein used to treat and prevent bleeding episodes in individuals with Hemophilia A, a genetic disorder where the body lacks sufficient Factor VIII. It works by temporarily raising plasma levels of Factor VIII, enabling proper blood coagulation.

Product Description:

Antihemophilic Factor (AH), also known as Factor VIII, is a crucial protein in the blood coagulation cascade, available in both plasma-derived and recombinant forms. It plays a central role in promoting normal clot formation in individuals with hemophilia A, a genetic disorder characterized by Factor VIII deficiency. The recombinant form of Antihemophilic Factor exhibits full coagulation-promoting activity, making it effective for preventing and controlling bleeding episodes.

Mechanistically, Antihemophilic Factor binds to Factor IXa in the presence of calcium ions and phospholipids, forming a complex that activates Factor X into Factor Xa. This activated complex subsequently converts prothrombin into thrombin, which then cleaves fibrinogen to form fibrin strands. The formation of fibrin ultimately stabilizes the blood clot, effectively controlling bleeding.

Antihemophilic Factor is indicated for the treatment and prophylaxis of bleeding episodes, as well as for surgical interventions in hemophilia A patients. Its recombinant form offers the advantages of high purity, consistent activity, and reduced risk of viral contamination compared to plasma-derived products. It is administered via intravenous infusion under the supervision of trained healthcare professionals, ensuring precise dosing and effective hemostatic control.